Concise Panel

1. SARS COV-2
2. Influenza A
3. Influenza B
4. Respiratory Syncytial Virus

Comprehensive Panel

Virus

1. SARS CoV-2
2. Influenza A-pan
3. Influenza A/H1N1
4. Influenza A/H3
5. Influenza A/H1N1 (2009)
6. Influenza B
7. RSV
8. Human parainfluenzavirus 1
9. Human parainfluenzavirus 2
10. Human parainfluenzavirus 3
11. Human parainfluenzavirus 4
12. Coronavirus OC43
13. Coronavirus 229E
14. Coronavirus NL63
15. Rhinovirus
16. Adenovirus
17. Human metapneumovirus

Bacteria

1. Bordetella parapertussis
2. Bordetella pertussis
3. Chlamydia pneumoniae
4. Mycoplasma pneumoniae

Accepted sample types are nasopharyngeal (NP), anterior nares (AN) swabs, and saliva. Validated sample types are lab-dependent.

VTM: 72 hours at 4ºC, MTM, ITM, and DNA/RNA Shield: 7 days at 20-23°C

A minimum of 3 mL sample volume is required.

A wide range of 3rd party saliva and Upper Respiratory VTM/UTM Collection Kits are available. Sample collection must be a 3 mL standard respiratory specimen collection device.

Accepted sample types are nasopharyngeal (NP) swabs, anterior nares (AN) swabs and saliva. Validated sample types are lab-dependent.

As performed at our Rockville, Maryland lab, the concise respiratory panel has the following sensitivity and specificity for each of the targets:

SARS-CoV-2 Sensitivity=96.25% Specificity=100% Influenza A Sensitivity)=97.5% Specificity=100% Influenza B Sensitivity=95% Specificity=100% Respiratory Syncytial Virus Sensitivity=95% Specificity=100%

*Data from PRL DC lab (PRL 167 VAL: PRL DC cRP ITM Assay Validation, Rev 1.0. 12/28/21). Tests run in each PRL laboratory are independently developed and validated at their respective facility; performance of tests may

PRL’s Concise Respiratory Panel has not received an emergency use authorization for the detection of SARS-CoV-2 or the diagnosis of or screening for COVID-19, and is not otherwise cleared, approved or authorized for any use by the U.S. Food and Drug Administration. The Concise Respiratory Panel is awaiting authorization by the State of New York Department of Health, which will permit PRL to perform the assay in New York. The Concise Respiratory Panel is available through our Rockville, MD lab.

We expect test results to be returned to the ordering entities within 24 hours.

87637

Description: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique.

Part number for the Concise Respiratory panel is 21000016. Part number for the Comprehensive panel is 21000001.

The test methodology is real-time reverse transcription polymerase chain reaction (RT-PCR).

PRL has 3 CLIA-certified labs (PRL NY: 33D2196459, PRL DC: 21D2215498, PRL OC: 05D2230382)

PRL has labs in Long Island, NY, Irvine, CA and Rockville, MD. PRL is exploring opening additional labs across the country.

At present, our Rockville, MD lab can receive samples from all states except Pennsylvania, New York and Rhode Island.